Tag: objectives

BELVIDERE, NJ, June 15, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today reminds shareholders to vote ahead of the Company’s Annual Meeting of Stockholders, which will be held on Wednesday, June 17, 2026, at 10:00 am Eastern Time. 

IRVINE, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (“CETY” or the “Company”) (Nasdaq: CETY), a clean energy technology company focused on sustainable energy and waste-to-value solutions, today announced the successful implementation of its advanced ORC component manufacturing initiative, which should substantially reduce production costs and improve supply chain efficiency for the Clean Cycle II (“CCII”) heat recovery systems.

The Supervisory Board of Eesti Energia AS, upon the proposal of Chairman of the Management Board, Andrus Durejko, has appointed Mr Gerrit Mäesalu as Chairman of the Management Board of Enefit OÜ and Member of the Management Board of Eesti Energia AS. Mäesalu’s term of office will commence on 19 June 2026 and continue until 1 April 2027.

SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.